Drug Trial Radar · NCT06029426
Study to Evaluate the Effects of Oral NMRA-335140 Versus Placebo in Participants With Major Depressive Disorder
Last checked: Nov 20, 2026Latest source record: Nov 26, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
383
Actual
Start
Sep 20, 2023
Primary completion
Dec 3, 2024
Study completion Jan 15, 2025
Sponsor
- Lead sponsor
- Neumora Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Sep 8, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a randomized, double blind, placebo controlled, multi-center study to evaluate the effects of NMRA-335140 (formerly BTRX 335140) on symptoms of depression in participants with Major Depressive Disorder (MDD). The study design consists of a Screening Period (up to 28 days), and a 6-week Treatment Period (during which participants will receive either NMRA-335140 or placebo). At the completion of the 6-week Treatment Period, participants who complete the study, provide informed consent, and meet the eligibility criteria may enter an extension study (NMRA-335140 501).
Conditions
- Major Depressive Disorder
Interventions
NMRA-335140Drug
Participants will receive NMRA-335140 at a dose of 80 mg QD, orally
PlaceboDrug
Placebo will be administered orally
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from Baseline to Week 6 in the Montgomery Asberg Depression Rating Scale (MADRS) total scoreTime frame: Baseline and up to Week 6
Locations
64 sites in 1 country. Site status is shown where the registry gives one.
Neumora Investigator Site
Huntsville, Alabama
Neumora Investigator Site
Phoenix, Arizona
Neumora Investigator Site
Bentonville, Arkansas
Neumora Investigator Site-1
Little Rock, Arkansas
Neumora Investigator Site
Little Rock, Arkansas
Neumora Investigator Site
Rogers, Arkansas
Neumora Investigator Site
Bellflower, California
Neumora Investigator Site
Garden Grove, California
Neumora Investigator Site
Glendale, California
Neumora Investigator Site
Imperial, California
Neumora Investigator Site
Lafayette, California
Neumora Investigator Site
Long Beach, California
Neumora Investigator Site
Los Angeles, California
Neumora Investigator Site
Oceanside, California
Neumora Investigator Site
Orange, California
Neumora Investigator Site
Riverside, California
Neumora Investigator Site
San Jose, California
Neumora Investigator Site #1
Sherman Oaks, California
Neumora Investigator Site
Sherman Oaks, California
Neumora Investigator Site
Temecula, California
Neumora Investigator Site
Torrance, California
Neumora Investigator Site
Colorado Springs, Colorado
Neumora Investigator Site
Gainesville, Florida
Neumora Investigator Site
Hallandale, Florida
Neumora Investigator Site
Jacksonville, Florida
Neumora Investigator Site
Lauderhill, Florida
Neumora Investigator Site
Maitland, Florida
Neumora Investigator Site
Miami, Florida
Neumora Investigator Site
Miami, Florida
Neumora Investigator Site
Miami, Florida
Neumora Investigator Site
Miami Lakes, Florida
Neumora Investigator Site
Orlando, Florida
Neumora Investigator Site
Tampa, Florida
Neumora Investigator Site
Marietta, Georgia
Neumora Investigator Site
Chicago, Illinois
Neumora Investigator Site
Evanston, Illinois
Neumora Investigator Site
Warrenville, Illinois
Neumora Investigator Site
Boston, Massachusetts
Neumora Investigator Site
Methuen, Massachusetts
Neumora Investigator Site
Watertown, Massachusetts
Showing 40 of 64 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.